Tizerpatida: a nova promessa contra a obesidade

Abstract

Obesity is a condition characterized by excessive accumulation of body fat, which can lead to various health risks. It is a chronic disease caused by genetic factors, endocrine dysfunctions, and lifestyle choices such as imbalanced diet and lack of physical activity. It can result in complications such as diabetes, dyslipidemia, cardiovascular diseases, and sleep disorders. It is estimated that over 1 billion people worldwide are obese, and this number will continue to increase. Obesity can be classified by Body Mass Index (BMI) or waist circumference. Adipose tissue, present in obesity, can lead to the development of type 2 diabetes. Obesity and type 2 diabetes are associated with serious health complications. Treatment involves weight reduction, diet, exercise, and behavioral therapy. Medications may be used when non-pharmacological treatment fails, and surgery can be an option in severe cases. Tirzepatide is a recently approved medication for the treatment of type 2 diabetes and obesity. It acts as a GLP-1 and GIP agonist, promoting glycemic control and weight loss. Studies show that tirzepatide may be more effective than other available medications. Further research is still needed to understand its efficacy, safety, and compare it to other available treatments